ArticleRenal failure2026
Riboflavin intake and kidney health: population evidence and mechanistic insights from NHANES and molecular docking analyses.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bisphenol A promotes esophageal carcinogenesis by activating the MMP1-PCOLCE regulatory axis and remodeling the tumor immune microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) constitutes a significant global public health challenge, with emerging evidence suggesting that riboflavin may confer renoprotective effects. However, the association between dietary riboflavin intake and CKD risk remains inadequately elucidated. To investigate this, we analyzed National Health and Nutrition Examination Survey (NHANES) 2005-2018 datasets using weighted multivariate logistic regression, interaction testing, stratified subgroup analyses, and curve fitting. Additionally, network pharmacology and molecular docking simulations were employed to identify and validate potential therapeutic targets. Our results showed that patients with CKD exhibited significantly lower riboflavin intake than their non-CKD counterparts (1.98 vs. 2.21 mg/d,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.